Effect of amitriptyline on the messenger RNA of thyroid hormone-responsive genes in rat cerebral tissue

Current Opinion in Psychiatry

Volumn 13, Issue 3, 2000, Pages 333-338

  Bobes, Julio ^a   McCann, Una D ^b  

^a UNIVERSITY OF OVIEDO   (Spain)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Depression; Gene expression; Thyroid hormones; Tricyclic antidepressants

Indexed keywords

METHADONE; NALTREXONE; OPIATE; PSYCHOSTIMULANT AGENT;

COGNITIVE THERAPY; COST CONTROL; DRUG DEPENDENCE; HEALTH CARE ACCESS; HEALTH CARE COST; HUMAN; METHADONE TREATMENT; METHODOLOGY; MOTIVATION; NONHUMAN; PSYCHOSOCIAL CARE; RELAPSE; REVIEW;

EID: 0034066019     PISSN: 09517367     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001504-200005000-00016     Document Type: Review

References (49)

1. 1 Koob GF, Le Moal M. Drug abuse: hedonic homeostatic dysregulation. Science 1997; 278:52-58.
2. 2 Nestler EJ, Aghajanian GK. Molecular and cellular basis of addiction. Science 1997; 278:58-63.
3. 3 Nestler EJ. Molecular mechanisms of opiate and cocaine addiction. Curr Opin Neurobiol 1997; 7:713-719.
4. 4 Rhodes T, Ball A, Stimson GV, Kobyshcha Y, Fitch C, Pokrovsky V, et al. HIV infection associated with drug injecting in the newly independent states, eastern Europe: the social and economic context of epidemics. Addiction 1999; 94:1323-1336.
5. 5 Lynskey M, White V, Hill D, Letcher T, Hall W. Prevalence of illicit drug use among youth: results from the Australian School Students' Alcohol and Drugs Survey. Aust NZ J Public Health 1999; 23:519-524. This study reports findings from the first national survey of illicit drug use among Australian school students, and indicates a high prevalence of illicit drug use. Comparisons of the findings from this study with earlier, regionally based surveys suggest an increase in the prevalence of cannabis use.
6. 6 Wallace Jr JM, Forman TA, Guthrie BJ, Bachman JG, O'Malley PM, Johnston LD. The epidemiology of alcohol, tobacco and other drug use among black youth. J Stud Alcohol 1999; 60:800-809.
7. 7 Chong MY, Chan KW, Cheng AT. Substance use disorders among adolescents in Taiwan: prevalence, sociodemographic correlates and psychiatric co-morbidity. Psychol Med 1999; 29:1387-1396. This article describes high rates of substance use disorders among adolescent persons in Taiwan.
8. 8 Carroll KM, Nich C, Sifry RL, Nuro KF, Franforter TL, Ball SA, Fenton L, et al. A general system for evaluating therapist adherence and competence in psychotherapy research in the addictions. Drug Alcohol Depend 1999; 57:225-238. This article describes The Yale Adherence and Competence Scale, a general system for evaluating therapist adherence and competence in delivering behavioral treatments for substance use disorders. It also summarizes 'the technology model of psychotherapy', which was recently developed to increase the rigor and measurement of psychosocial treatments of drug abuse.
9. 9 Chutuape MA, Silverman K, Stitzer M. Contingent reinforcement sustains post-detoxification abstinence from multiple drugs: a preliminary study with methadone patients. Drug Alcohol Depend 1999; 54:69-81.
10. 10 Silverman K, Chutuape MA, Bigelow GE, Stitzer ML. Voucher-based reinforcement of cocaine abstinence in treatment-resistant methadone patients: effects of reinforcement magnitude. Psychopharmacology (Berl) 1999; 146:128-138. This study demonstrated that cocaine abstinence among treatment-resistant cocaine-abusing heroin addicts can be increased by increasing the value of vouchers used in a voucher-based contingency management therapy. Reinforcement magnitude was a critical determinant of the effectiveness of this abstinence reinforcement intervention.
11. 11 Preston KL, Silverman K, Umbricht A, DeJesus A, Montoya ID, Schuster CR. Improvement in naltrexone treatment compliance with contingency management. Drug Alcohol Depend 1999; 54:127-135. This study demonstrated that voucher incentives can significantly increase adherence to naltrexone maintenance in recently detoxified opioid-dependent individuals.
12. 12 Bammer G, Dobler-Mikola A, Fleming PM, Strang J, Uchtenhagen A. The heroin prescribing debate: integrating science and politics. Science 1999; 284:1277-1278. This is a review of the advantages and disadvantages of the heroin trials and the history of heroin prescription in the UK. An interesting discussion is provided of the conclusions that can be drawn from the results of the Swiss Heroin Trial and requirements for new trials and methodologic difficulties that they will face. This brave article advocates that, if high-quality empiric evidence is found, then a possible medicalization, rather than legalization, of heroin may not only be justified but advisable.
13. 13 United Nations International Drug Control Programme, World Drug Report. Oxford: Oxford University Press; 1997.
14. 14 D'Ippoliti D, Davoli M, Perucci CA, Pasqualini F, Bargagli AM. Retention in treatment of heroin users in Italy: the role of treatment type and of methadone maintenance dosage. Drug Alcohol Depend 1998; 52:167-171. This study of 1500 Italian opiate addicts showed that methadone maintenance patients do better than naltrexone-treated patients long term, remaining in treatment 30% more than those in abstinence-oriented centers. Also, the higher the dose of methadone, the better the patients do.
15. 15 Strain EC, Bigelow GE, Liebson IA, Stitzer ML. Moderate- vs high-dose methadone in the treatment of opioid dependence: a randomized trial. JAMA 1999; 281:1000-1005. In a 40-week randomized double-blind trial at Johns Hopkins, urine analysis and retention in treatment was assessed in 97 patients allocated to moderate doses (40-50 mg/day) and 95 patients to high doses (80-100 mg/day) of methadone. The same group had previously shown that moderate doses were more effective than low doses (20 mg/day).
16. 16 Wasserman DA, Weinstein MG, Havassy BE, Hall SM. Factors associated with lapses to heroin use during methadone maintenance. Drug Alcohol Depend 1998; 52:183-192. This research suggests that factors that influence lapses are similar across drug treatment populations.
17. 17 Morral AR, Belding MA, Iguchi MY. Identifying methadone maintenance clients at risk for poor treatment response: pretreatment and early progress indicators. Drug Alcohol Depend 1999; 55:25-33. The findings of this study suggest that, although client characteristics at program admission might provide little guidance in treatment planning, client performance early in treatment might offer an especially powerful indicator that could be used to guide subsequent treatment planning.
18. 18 Joe GW, Simpson DD, Broome KM. Retention and patient engagement models for different treatment modalities in DATS. Drug Alcohol Depend 1999; 57:113-125.
19. 19 McHugh PR, Slavney PR. The perspectives of psychiatry. Baltimore, MD: Johns Hopkins University Press; 1998.
20. 20 Bigelow GE, Brooner RK, Silverman K. Competing motivations: drug reinforcement vs non-drug reinforcement. J Psychopharmacol (Oxf) 1998; 12:8-14. A provocative opinion piece regarding the behavioral basis for drug use and abuse is presented.
21. 21 Kidorf M, Hollander JR, King VL, Brooner RK. Increasing employment of opioid dependent outpatients: an intensive behavioral intervention. Drug Alcohol Depend 1998; 50:73-60. This study evaluated the success of a new treatment requirement that patients who had been maintained on methadone for 12 months gain employment (20 h/week, paid or volunteer) using a behavioral contingency paradigm. Of the patients 75% secured employment and maintained the position for at least 1 month. Most patients (78%) continued working throughout the 6-month follow up. These results demonstrate that behavioral contingencies can motivate many methadone maintenance patients to obtain employment.
22. 22 Kidorf M, King VL, Brooner RK. Integrating psychosocial services with methadone treatment: behaviorally contingent pharmacotherapy. In: Methadone treatment for opioid dependence. Strain EC, Stitzer ML (editors). Baltimore, MD: Johns Hopkins University Press; 1999. pp. 166-195.
23. 23 Fischer G, Gombas W, Eder H, Jagsch R, Peternell A, Stuhlinger G, et al. Buprenorphine versus methadone maintenance for the treatment of opioid dependence. Addiction 1999; 94:1337-1347. This report describes an open study that compared the efficacy of buprenorphine versus methadone in 60 opiate addicts over a 24-week period. Both drugs were effective for some patients. The retention rate was significantly better in the methadone maintained group, however, whereas those in the buprenorphine group had significantly lower rates of illicit opiate consumption.
24. 24 Rawson RA, Hasson AL, Huber AM, McCann MJ, Ling W. A 3-year progress report on the implementation of LAAM in the United States. Addiction 1998; 93:533-540.
25. 25 Steffen T, Uchtenhagen A, Gutzwiller F, Dobler-Mikola A, Blattler R. [Heroin-assisted treatment of opiate dependent patients. Experiences from Swiss trials for medical prescription of narcotics]. Internist (Berl) 1999; 40(6):651-656.
26. 26 Perneger TV, Giner F, del Rio M, Mino A. Randomized trial of heroin maintenance programme for addicts who fail in conventional drug treatments. BrMedJ 1998; 317:13-18. This study, a substudy of the 'Swiss Heroin Trial', compared two groups of heroin addicts recruited from the community who were socially marginalized and in poor health and had failed in at least two previous drug treatments. Twenty-seven individuals received intravenous heroin treatment as outpatients for 6 months, whereas the control group of 24 individuals received conventional drug treatment. At the end of 6 months, only one patient in the heroin group, and 10 patients in the control group continued to use street heroin. Those in the heroin group had larger improvements in psychiatric health measures, social functioning, and illegal activities related to drug use.
27. 27 Satel SL, Aeschbach E. The Swiss heroin trials: scientifically sound? J Subst Abuse Treat 1999; 17:331-335.
28. 28 Bammer G, Dobler-Mikola A, Fleming PM, Strang J, Uchtenhagen A. The heroin prescribing debate: integrating science and politics. Science 1999; 21;284(5418):1277-8.
29. 29 Schwartz RP, Brooner RK, Montoya ID, Currents M, Hayes M. A 12-year follow-up of a methadone maintenance program. Am J Addiction 1999; 8:293-299.
30. 30 O'Connor PG, Oliveto AH, Shi JM, Triffleman EG, Carroll KM, Kosten TR, et al. A randomized trial of buprenorphine maintenance for heroin dependence in a primary care clinic for substance users versus a methadone clinic. Am J Med 1998; 105:100-105. Forty-six patients were randomized to buprenorphine treatment in a primary care setting versus traditional drug abuse treatment. Retention in a primary care setting was better than that in a traditional drug abuse treatment setting. Patients were less likely to have opioid-positive urine and more likely to have 3 successive weeks of abstinence.
31. 31 Nemes S, Wish ED, Messina N. Comparing the impact of standard and abbreviated treatment in a therapeutic community. J Subst Abuse Treat 1999; 17:339-347.
32. 32 Robles E, Silverman K, Preston KL, Cone EJ, Katz E, Bigelow GE, Stitzer ML. The brief abstinence test: voucher-based reinforcement of cocaine abstinence. Drug Alcohol Depend 2000; 58:205-212.
33. 33 Chutuape MA, Silverman K, Stitzer ML. Use of methadone take-home contingencies with persistent opiate and cocaine abusers. J Subst Abuse Treat 1999; 16:23-30.
34. 34 Silverman K, Wong CJ, Umbricht-Schneiter A, Montoya ID, Schuster CR, Preston KL. Broad beneficial effects of cocaine abstinence reinforcement among methadone patients. J Consult Clin Psychol 1998; 66:811-824.
35. 35 Preston KL, Silverman K, Higgins ST, Brooner RK, Montoya I, Schuster CR, Cone EJ. Cocaine use early in treatment predicts outcome in a behavioral treatment program. J Consult Clin Psychol 1998; 66:691-696.
36. 36 Crits-Christoph P, Siqueland L, Blaine J, Frank A, Luborsky L, Onken LS, et al. Psychosocial treatments for cocaine dependence: National Institute on Drug Abuse Collaborative Cocaine Treatment Study. Arch Gen Psychiatry 1999; 56:493-502. This outstanding study from the National Institute on Drug Abuse Collaborative Cocaine Treatment Study opens new horizons in the evaluation and treatment of cocaine dependence.
37. 2 receptor levels. Am J Psychiatry 1999; 156:1440-1443.
38. 38 Uslaner J, Kalechstein A, Richter T, Ling W, Newton T. Association of depressive symptoms during abstinence with the subjective high produced by cocaine. Am J Psychiatry 1999; 156:1444-1446.
39. 39 Childress AR, Mozley PD, McElgin W, Fitzgerald J, Reivich M, O'Brien CP. Limbic activation during cue-induced cocaine craving. Am J Psychiatry 1999; 156:11-18.
40. 40 Romach MK, Glue P, Kampman K, Kaplan HL, Somer GR, Poole S, Clarke L, Coffin V, Cornish J, O'Brien CP, Sellers EM. Attenuation of the euphoric effects of cocaine by the dopamine D1/D5 antagonist ecopipam. Arch Gen Psychiatry 1999; 56(12):1101-6. A study of a novel and selective D1/D5 antagonist, ecopipam (SCH 39166), on subjective responses to intravenous cocaine in 11 subjects with cocaine dependence. Results indicated a significant, dose-related reduction in cocaine's stimulant and euphoric effects, in addition to a reduction in the desire to use cocaine. In addition to adding to the growing body of literature indicating an important role for the brain DA system in the rewarding effects of abused drugs, these results hold promise for pharmacological treatments approaches for cocaine addiction.
41. 41 Flynn PM, Kristiansen PL, Porto JV, Hubbard RL. Costs and benefits of treatment for cocaine addiction in DATOS. Drug Alcohol Depend 1999; 57:167-174.
42. 42 Carroll KM, Nich C, Ball SA, McCance E, Rounsaville BJ. Treatment of cocaine and alcohol dependence with psychotherapy and disulfiram. Addiction 1998; 93:713-728.
43. 43 Levin FR, Evans SM, Kleber HD. Prevalence of adult attention-deficit hyperactivity disorder among cocaine abusers seeking treatment. Drug Alcohol Depend 1998; 52:15-25.
44. 44 Albertson TE, Deriet RW, Van Hoozen BE. Methamphetamine and the expanding complications of amphetamines. West J Med 1999; 170:214-219.
45. 45 Huber A, Ling W, Shoptaw S, Gulati V, Brethen P, Rawson R. Integrating treatments for methamphetamine abuse: a psychosocial perspective. J Addict Dis 1997; 16:41-50.
46. 46 Melega WP, Lacan G, Desalles AA, Phelps ME. Long-term methamphetamine-induced decreases of [(11)C]WIN 35,428 binding in striatum are reduced by GDNF: PET studies in the vervet monkey. Synapse 2000; 35:243-249.
47. 47 Wallace TL, Gudelsky GA, Vorhees CV. Methamphetamine-induced neurotoxicity alters locomotor activity, Stereotypic behavior, and stimulated dopamine release in the rat. J Neurosci 1999 Oct 15; 19(20):9141-8.
48. 48 Villemagne V, Yuan J, Wong DF, Dannals RF, Hatzidimitriou G, Mathews WB, et al. Brain dopamine neurotoxicity in baboons treated with doses of methamphetamine comparable to those recreationally abused by humans: evidence from [11C]WIN-35,428 positron emission tomography studies and direct in vitro determinations. J Neurosci 1998; 18:419-427.
49. 49 McCann UD, Wong DF, Yokoi F, Villemagne V, Dannals RF, Ricaurte GA. Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users: evidence from positron emission tomography studies with [11C]WIN-35,428. J Neurosci 1998; 18:8417-8422.